Drug Profile
Research programme: PROTAC therapeutics - Arvinas
Alternative Names: ARCC-29; ARV-378; ARV-771; BET-PROTAC ARV-771; Hydrophobic Tagging small molecules - Arvinas; HyT small molecules - Arvinas; PROTAC ARV-771; PROTAC ARV-825; PROTACs - Arvinas; Protein-targeting chimeric molecules - Arvinas; Proteolysis Targeting Chimeric molecules - ArvinasLatest Information Update: 23 Jan 2023
Price :
$50
*
At a glance
- Originator Arvinas
- Developer Arvinas; Yale University
- Class Anti-inflammatories; Antineoplastics; Small molecules
- Mechanism of Action Androgen receptor degradation enhancers; Estrogen receptor alpha degradation enhancers; Proteolysis; Ubiquitin protein ligase complex modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
- No development reported Autoimmune disorders; Breast cancer; Inflammation; Prostate cancer
Most Recent Events
- 10 Dec 2022 ARV 825 is still in preclinical trials for Haematological malignancies in USA
- 10 Dec 2022 Pharmacodynamics data from a preclinical studies in Haematological malignancies presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-2022)
- 25 Apr 2022 Arvinas and Genentech co-own four patents in the US directed to PROTAC targeted protein degrader compounds addressing a specific protein